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Introduction: Acquired von Willebrand disease is initiated by autoantibodies and hyperviscosity syndrome caused
by a massive polyclonal hypergammaglobulinemia. Acquired von Willebrand disease associated with autoimmune
disease in addition to pulmonary hypertension during emergency room presentation is a rare condition. To the
best of our knowledge, this is the second case reported in the literature treated with success; the first one was
reported in 1987.
Case presentation: A 28-year-old mestizo man with a 3-year history of inflammatory arthritis was admitted to our
hospital. An overlap of rheumatoid arthritis with systemic lupus erythematosus was suspected; therefore
methotrexate was initiated, and later changed to leflunomide because of liver toxicity. Prothrombin time,
international normalized ratio and activated partial thromboplastin times were normal (11/10.4 seconds; 1.2; 31.1/
26.9 seconds, respectively), von Willebrand factor activity was observed with low ristocetin cofactor at 33.6UI/dL,
high von Willebrand factor antigen >200UI/dL, and a low von Willebrand factor: ristocetin cofactor to von
Willebrand factor antigen ratio. He was admitted to the emergency room with a 24-hour evolution of progressive
dyspnea, cough, thoracic pain, and palpitations, 104 beats/min, 60/40 mmHg, temperature of 38°C, pulse oximetric
saturation 88% and 30 breaths/minute. Cold, pale and mottled skin was also observed. He was then transferred to
the intensive care unit. The placement of a pulmonary artery catheter was made. The initial patterns showed a
precapillary pulmonary hypertension; acute pulmonary embolism was the first choice for diagnosis. Pulmonary
angiography was conducted, and when no clot was discovered, pulmonary artery hypertension associated with
connective tissue disease was considered. Serum protein electrophoresis confirmed the presence of a massive
polyclonal hypergammaglobulinemia, and no paraproteinemia or monoclonal cell population was found from the
electrophoretic pattern of the patient’s plasma. Hypergammaglobulinemia was the cause of hyperviscosity
syndrome associated with autoantibodies. Three sessions of plasma exchange therapy were made, and clinical
improvement was observed. He was then discharged from the intensive care unit and hospital, respectively. He is
now attended by an external consult and has no respiratory symptomatology.
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Conclusions: Hyperviscosity syndrome with pulmonary arterial hypertension presentation in a patient with
acquired von Willebrand disease in an autoimmune context is a rare condition that can be treated successfully with
plasmapheresis and critical care support.
Keywords: Acquired von Willebrand disease, Hyperviscosity syndrome, Pulmonary arterial hypertension,
Rheumatoid arthritisIntroduction
Acquired von Willebrand disease (aVWD) is initiated by
autoantibodies and hyperviscosity syndrome (HVS) caused
by a massive polyclonal hypergammaglobulinemia. AVWD
associated with autoimmune disease in addition to pul-
monary hypertension during emergency room (ER) pres-
entation is a rare condition. Plasma cell neoplasm is the
most common cause of HVS, mainly Waldenström mac-
roglobulinemia and multiple myeloma, diseases character-
ized by a monoclonal paraprotein [1]. Three mechanisms
for aVWD have been proposed: a) aggregation of immuno-
globulins (Igs) dependent upon the factor region [2], b)
interaction between IgM rheumatoid factor and inter-
mediate complexes formed by IgG aggregates [3], and c)
IgG intermediate complexes alone [4]. Viscosity refers to
resistance to flow, or stickiness, and is measured by
the time required for a serum or plasma sample to
flow through a capillary tube (Ostwald tube) under the
influence of gravity [5]. Sjögren syndrome, rheumatoid
arthritis (RA), systemic lupus erythematosus (SLE),
cryoglobulinemia, and human immunodeficiency virus
infection are rarely associated with HVS [6].
According to the Scientific and Standardization Com-
mittee of the International Society of Thrombosis and
Haemostasis registry, autoimmune disorders are the
cause of aVWD in only 2% of cases [7]. RA diagnosis
and the presence of antinuclear antibodies could be an
epiphenomenon, which has been previously described
[8]. However, the pathophysiology of aVWD is heteroge-
neous, and in most cases there is an increased clearance,
inhibition or proteolysis of von Willebrand factor
(VWF) in the plasma [9]. The first two mechanisms had
been reported in SLE due to circulating IgG antibodies
directed against either nonfunctional or functional do-
mains of VWF [10].
In addition, it has been reported that during pulmon-
ary hypertension, plasminogen activator inhibitor-1
(PAI-1) levels are high, suggesting a loss of fibrinolytic
activity [11], however, PAI-1 was not determinate in our
patient. The hemodynamic pattern has also been de-
scribed by Condliffe et al. [12] who studied patients with
connective tissue diseases and pulmonary arterial hyper-
tension (PAH), as well as 28 patients with isolated SLE
and PAH. Murata et al. [13] reported a case of PAH with
Raynaud phenomenon and relative polycythemia wherethe right cardiac catheterization showed PAH with pul-
monary artery pressures of 93/39mmHg (mean pressure
60mmHg), cardiac index of 2.2L/minute/m2, and a pul-
monary vascular resistance index of 1219dyne·second/
(cm5·m2). Patients with SLE and PAH not related with
an incidence of hyperviscosity were found to have 1-year
and 3-year survival rates of 78% and 74%, respectively,
and patients with RA had 1-year and 3-year survival
rates of 83% and 63%, respectively [12]. Here, we present
a rare association of aVWD, PAH and RA. To the best
of our knowledge, this is the second case reported in the
literature treated with success. The first one was reported
by Eaton and colleagues in 1987 [14]; they treated a pa-
tient with RA, serum hyperviscosity and secondary pul-
monary hypertension, with a mean pulmonary arterial
pressure of 53mmHg and pulmonary vascular resistance
of 707dyne·second/cm2.
Case presentation
A 28-year-old mestizo man with a 3-year history of in-
flammatory arthritis and dry mouth and eyes was admit-
ted to our hospital. He was admitted to our hospital at
the request of an external consultant in January 2008;
the initial laboratory evaluation is listed in Table 1.
Methotrexate was initiated with good response; 1 year
later methotrexate was changed to leflunomide because
of liver toxicity. Globulin levels at admission and 1 year
after were 5.2 and 7.2g/dL, respectively. Of interest, al-
though he also had positive anti-double-stranded deoxy-
ribonucleic acid (DNA) and anti-nucleosomes antibodies,
which normally have a higher specificity for the diagnosis
of SLE, at admission we could not make a diagnosis be-
cause of the absence of clinical manifestations other than
arthritis and sicca.
Hyperemia and mild eye pain appeared in March
2009, and a diffuse scleritis was diagnosed. Therefore
leflunomide was suspended and he received prednis-
one (1mg/kg), tapered to 5mg/day in 1 month and
suspended after another month because a mouth ulcer
appeared.
Multiple important mucosal bleeding episodes (epi-
staxis and gingival hemorrhage) started in 2009, and co-
agulation tests were conducted through 2010, with the
following results: prothrombin time, international nor-
malized ratio and activated partial thromboplastin times
Table 1 Laboratory data at hospital: external consultant
admission
Test Value Normal value
Anticitrulline antibodies 268U/mL ≤25U/mL



















Table 2 Laboratory data at emergency room admission
Arterial blood gas at room air
pH 7.45, PaO2 51.6mmHg, PaCO2 14.7mmHg, HCO3 10.6, standard









Total bilirubin 3.3mg/dL 0.2–1.3mg/dL









Immunoglobulin G 3702mg/dL 700–1600mg/dL
Immunoglobulin M 542mg/dL 40–230mg/dL
Immunoglobulin A 372mg/dL 70–400mg/dL
Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase,
BE base excess, BUN blood urea nitrogen, HCO3 bicarbonate, PaCO2 partial
pressure of carbon dioxide in arterial blood, PaO2 partial pressure of oxygen in
arterial blood, SaO2, saturation level of oxygen in hemoglobin.
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respectively), VWF activity was observed with low
ristocetin cofactor (RCo) at 33.6UI/dL, high VWF anti-
gen (VWF:Ag) >200UI/dL, and a low VWF:RCo to
VWF:Ag ratio. Furthermore, an Ivy bleeding time test of
more than 15 minutes and normal factor VIII activity
(70UI/dL) were observed. An in vitro test showed that
the patient’s IgG inhibited the VWF:RCo of normal
plasma, therefore the RCo activity inhibition test was
positive, although this was not necessary for the diagno-
sis. A characteristic aVWD laboratory test with the iden-
tification of a causal underlying disease, integrated the
diagnosis [15].
The patient was admitted to the ER in April 2011 with
a 24-hour evolution of progressive dyspnea, cough,
thoracic pain, and palpitations, 104beats/minute, 60/
40mmHg, temperature of 38°C, pulse oximetric satur-
ation 88% and 30 breaths/minute. Cold, pale and mot-
tled skin was also observed; laboratory values at ER
admission are listed in Table 2. There were no signs of
arthritis or bleeding. Initial crystalloid reanimation was
made with partial response, and persistent tachypnea
and hypoxemia (arterial oxygen tension/fraction of in-
spired oxygen = 245.7) precluded a rapid intubation se-
quence. He was then transferred to the intensive care
unit (ICU) 12 hours later. Initial laboratory ER patient
data are listed in Table 2; Acute Physiology and Chronic
Health Evaluation II and Sequential Organ Failure As-
sessment values at ICU admission were 11 and 27 points
respectively.An electrocardiogram showed an incomplete right
bundle block not previously detected. A chest X-ray
revealed no infiltrates, and complementary laboratory
tests did not suggest a related infection. The place-
ment of a pulmonary artery catheter (PAC) was made
under the indication of a differentiation between car-
diogenic and non-cardiogenic shock (see Table 3).
The initial patterns showed a precapillary pulmonary
hypertension; therefore, in the autoimmune context of
the patient, although serial negative antiphospholipid
antibodies were noted in his history, acute pulmonary
embolism was the first choice for diagnosis. Pulmon-
ary angiography was conducted, and when no clot
was discovered, PAH associated with connective tissue
disease was considered because pulmonary hyperten-
sion has been historically associated with connective
tissue diseases.
These PAC parameters were the same as observed
by Condliffe et al. [12] and Murata et al. [13] except
for the pulmonary vascular resistance index, which
Table 3 Pulmonary artery catheter patterns






MAP (mmHg) 73 60 63 72 78
HR (beat/minute) 130 103 113 110 118
PAOP (mmHg) 14 14 14
PASP (mmHg) 56 58 66
PADP (mmHg) 50 43 45
MPAP (mmHg) 53 48 52
CI (L/minute/m2) 2.04 2.33 2.1 2.5 3.4
SV (mL) 24.5 36.9 30.8 36.3 47
SVRI (dyne·second/(cm5·m2)) 2262 1956 1880
PVRI (dyne·second/(cm5·m2)) 1525 995 1419
SvO2 (mmHg) 42 67.4
Lactate (mg/dL) 4.2 1.7
Abbreviations: CI, cardiac index; HR, heart rate; MAP, mean arterial pressure; MPAP, mean pulmonary artery pressure; PADP, pulmonary artery diastolic pressure;
PAOP, pulmonary artery occlusion pressure; PASP, pulmonary artery systolic pressure; PVRI, pulmonary vascular resistance index; SV, stroke volume; SvO2, venous
oxygen saturation; SVRI, systemic vascular resistance index.
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Condliffe et al. cases (715 versus 1525 dyne·second/
(cm5·m2)). Because connective tissue disease may
cause PAH because of the vasculature pathology, the
difference in more severe resistance may be explained
by the changes in the rheological properties (1 poise
(P) = 1g·(second·cm)−1 = 1dyne·second/cm2) present
in the HVS, where a decrease in the blood flow can
explain the resistance increase. Laboratory blood sam-
ples hinted about the thickness of blood, so viscosity
was measured and found to be 65.8cP (<1.9cP).
Lymphadenopathy and organomegaly were ruled out.
A bone marrow biopsy did not show clonality of plasma
cells. Serum protein electrophoresis confirmed the pres-
ence of a massive polyclonal hypergammaglobulinemia,
and no paraproteinemia or monoclonal cell population
was found from the electrophoretic pattern of the pa-
tient’s plasma. Hypergammaglobulinemia was the cause
of HVS associated with autoantibodies. Three sessions
of plasma exchange therapy were made. Albumin and
frozen fresh plasma were used as the expander, and one
circulating blood volume was utilized. Significant men-
tal, hemodynamic recovery and clinical outcomes be-
came evident. A negative Q value was observed in the
HVS in this patient after taking into account the
Starling vascular permeability formula, where the mi-
crovasculature is influenced by protein content and
transcapillary fluid flux, specifically, where Q is equal to
volume of flow across the capillary wall. This finding led
to the conclusion that dilution of protein content may
alleviate the HVS, and the fluid administration was con-
sidered supportive therapy with judicious considerationof the compartment shift of the solutions. His renal
function returned to basal state and he was extubated
on day 7 of ICU admission. He was then discharged
from the ICU and hospital, respectively with good prog-
nosis (Charlson comorbidity index of 0 points).
The patient now attends external consult without re-
spiratory symptoms. One month after hospital discharge
his arthritis returned and methotrexate was resumed
with good clinical response. Hydroxychloroquine with
steroids were initiated because of persistent elevated
anti-double stranded DNA (last value at February 2013,
20.2U/mL), no bleeding sign had been present with per-
sistent positive VWF:Ag values.
Conclusions
HVS with PAH presentation in a patient with aVWD in
an autoimmune context is a rare condition that can be
treated successfully with plasmapheresis and critical care
support.
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